Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production

Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent azacytidine, achieves complete remission with or without count recovery in ∼70% of treatment-naive elderly patients unfit for conventional intensive chemotherapy. However, the mechanism of action of this drug combination is...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jong Bok, Khan, Dilshad H., Hurren, Rose, Xu, Mingjing, Na, Yoosu, Kang, Hyeonjeong, Mirali, Sara, Wang, Xiaoming, Gronda, Marcela, Jitkova, Yulia, MacLean, Neil, Arruda, Andrea, Alaniz, Zoe, Konopleva, Marina Y., Andreeff, Michael, Minden, Mark D., Zhang, Li, Schimmer, Aaron D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310428/
https://www.ncbi.nlm.nih.gov/pubmed/34292323
http://dx.doi.org/10.1182/blood.2020009081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310428/
https://www.ncbi.nlm.nih.gov/pubmed/34292323
http://dx.doi.org/10.1182/blood.2020009081

Ejemplares similares